...
首页> 外文期刊>Experimental & molecular medicine. >Hepatocellular carcinoma: old friends and new tricks
【24h】

Hepatocellular carcinoma: old friends and new tricks

机译:肝细胞癌:老朋友和新技巧

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis, during which liver cells undergo chronic cycles of necrosis and regeneration. The complex genomic landscape of HCC has been extensively investigated to draw correlations between recurrently mutated pathways and patient prognosis. However, our limited success with targeted therapy shows that knowing the presence of somatic mutations alone is insufficient for us to gauge the full spectrum of their functional consequences in the context of tumor evolution. In addition, the current molecular classification of HCC offers little information on the relationship between the molecular features and immunological properties of HCC tumors and their immune microenvironment. This review introduces current challenges and advancements made in HCC surveillance, diagnosis, and treatment. We also discuss the suite of HCC-associated genetic changes and describe recent studies that provide evidence for an evolving functional model and its implications for understanding and targeting HCC progression. Liver cancer: Call to explore evolving mutations within tumors Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide, but despite advances in understanding disease genetics, successful targeted therapies are limited. Eunsun Kim at Stanford University and Patrick Viatour at the University of Pennsylvania reviewed current HCC surveillance, diagnostics and treatments, focusing on genetic changes and their influence on disease progression. Novel methods for HCC diagnosis, including analysis of cancer-derived materials in blood, will complement existing diagnostics and help identify more early stage cases. Extensive studies of HCC tumor ecosystems will inform the development of novel immunotherapies. More studies involving genetic sequencing of mutations within tumors over time should further advance our understanding of HCC progression and help explain varying treatment responses.
机译:肝细胞癌(HCC)是最普遍的原发性肝癌和全世界癌症相关死亡的主要原因。 9%的HCC病例出现来自肝硬化,在此期间肝细胞经历慢性循环的坏死和再生。 HCC的复杂基因组景观已被广泛研究,以利用常规突变的途径与患者预后之间的相关性。然而,我们对有针对性的治疗的有限成功表明,知道单独的体细胞突变的存在不足以使我们在肿瘤演化的背景下衡量其功能后果的全部谱。此外,HCC的当前分子分类提供了关于HCC肿瘤的分子特征和免疫特性与其免疫微环境之间的关系的信息。本综述介绍了HCC监测,诊断和治疗所取得的当前挑战和进步。我们还讨论了HCC相关的遗传变化套件,并描述了最近的研究,为不断变化的功能模式提供了证据及其对理解和瞄准HCC进展的影响。肝癌:呼吁探讨肿瘤内的演变突变肝细胞癌(HCC)是全世界最常见的原发性肝癌,但尽管了解疾病遗传学的进步,所以成功的有针对性的疗法受到限制。在宾夕法尼亚州斯坦福大学和帕特里克·沃阿特·帕特里克·斯科姆审查了当前的HCC监控,诊断和治疗,重点是遗传变化及其对疾病进展的影响。新型HCC诊断方法,包括分析血液中的癌症衍生材料,将补充现有的诊断,并有助于确定更多早期阶段案件。对HCC肿瘤生态系统的广泛研究将提供新型免疫治疗的发展。更多研究涉及随时间肿瘤突变的遗传测序应进一步推进我们对HCC进展的理解,并帮助解释不同的治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号